Mazdutide
Also known as: IBI362, LY3305677
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
An investigational dual GLP-1 and glucagon receptor agonist studied for weight management and metabolic outcomes, with a notable trial program in China.
What it is & how it works
What it is
Mazdutide is an investigational dual GLP-1/glucagon agonist, developed with a prominent late-stage trial program in China.
How it is thought to work
Like other dual agonists, it pairs GLP-1’s appetite and glucose effects with glucagon-receptor activity hypothesized to raise energy expenditure.
The evidence and the caveat
Human data is maturing and regional regulatory progress is real, but it is not a broadly approved therapy. Non-trial product is unapproved and unverified.
What it's discussed & studied for
- Obesity / weight management (investigational)
- Metabolic outcomes (under study)
Discussion of a use is not a claim that it works or is approved.
Research status
Investigational; human trials ongoing, with prominent late-stage studies in China. Not broadly approved.
Evidence quality
Human trial data exists and is maturing; regulatory status varies by region and it is not an approved therapy in most markets.
Dosing discussion
Defined within clinical trials only; no broadly approved label.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Gastrointestinal effects are common, as with the class. The glucagon component is still being characterized. Not a broadly approved therapy.
Sourcing literacy
Research-market versions are unapproved and unverified regardless of regional trial progress.
Selected literature
FAQ
How is mazdutide similar to survodutide?
Both are dual GLP-1/glucagon agonists. They are developed by different companies and have distinct trial programs.
Is it approved?
It is investigational; regulatory progress is most advanced in China and it is not an approved therapy in most markets.